31/08/2017 07:11:46

NeuroSearch A/S – H1 report 2017

Related content
05 Dec - 
Update on NeuroSearch’s business status and future
17 Nov - 
NeuroSearch upgrades its guidance for 2017
04 Jul - 
NeuroSearch and Saniona enter into agreement on transfe..
Related debate
20 Apr - 
Ja, det bør kunne lade sig gøre at finde en køber, så d..
20 Apr - 
ja - ikke at forglemme værdier i de mange rettigheder t..
20 Apr - 
Jeg tror/håber, at der kommer købstilbud inden generalf..

Announcement

31 August 2017

 

Below please find the H1 report 2017. The full report is available in the enclosed PDF file.

The NeuroSearch Group posted an operating loss of DKK 2.3 million in H1 2017 (H1 2016: a loss of DKK 1.4 million).

A loss after tax of continuing operations of DKK 2.5 million was posted in H1 2017 (H1 2016: a loss of DKK 1.7 million).

A consolidated net loss of DKK 2.5 million was posted for H1 2017 (H1 2016: a net loss of DKK 0.5 million).

At 30 June 2017, cash and cash equivalents totalled DKK 66 million (30 June 2016: DKK 77 million). In H1 2017, NeuroSearch paid the DKK 5 million fine for market manipulation.

Update on the Company’s assets.

The Company has shareholdings in:

  • NsGene: 26.8% (NsGene entered into voluntary liquidation on 30 January 2017. NeuroSearch has recognised proceeds from the liquidation of DKK 4.5 million in its financial statements for 2016, which the Company expects to receive in Q3 2017).

  • Atonomics: 3.6%.

Licence agreements:

  • Potential milestone payments from Teva Pharmaceuticals (if Huntexil® is granted market approval, NeuroSearch will be entitled to receive milestone payments totalling up to DKK 55 million. In 2016, Teva Pharmaceutical Industries Ltd. announced positive data from a comprehensive Phase II study. NeuroSearch has no further insight into Teva’s future plans for developing Huntexil® and is therefore unable to assess the likelihood of payments to NeuroSearch being triggered or the timing of such payments. NeuroSearch has initiated a process to identify any possibilities of divesting the Company’s entitlement to potential milestone payments and potential royalties.).

  • Agreements with Saniona A/S. See more below in “Events after the balance sheet date”.

Except for the proceeds deriving from the liquidation of NS Gene, the value of the assets listed above is subject to substantial uncertainty as no established market exists for such assets.

 

In addition, NeuroSearch calculated the value as of 31 December 2016 of its unrecognised tax losses carried forward at approximately DKK 1,708 million, and deductible temporary differences at approximately DKK 84 million, or a total of approximately DKK 1,791 million. Under certain conditions, the unrecognised tax assets may be utilised in full or in part by a potential buyer of NeuroSearch.

Outlook for 2017

In 2017, NeuroSearch expects an operating loss in the range of DKK 2.3-3.3 million. The outlook does not include any income from the possible divestment of additional Company assets or potential income from the Company’s agreement with Teva.

Events after the balance sheet date

On 4 July 2017, NeuroSearch and Saniona entered into an agreement on transfer of the remaining rights in the preclinical and clinical assets which NeuroSearch divested to Saniona during the period 2012-2016. In full and final settlement of NeuroSearch’s remaining rights in the divested programs, NeuroSearch received from Saniona a one-time cash payment of DKK 5.5 million. Furthermore, Saniona assumed NeuroSearch’s royalty obligations to third parties regarding potential future net sales of products from the programs, including NeuroSearch’s royalty payment obligations to Boehringer Ingelheim (tesofensine) and to GlaxoSmithKline (NS2359).

Of the DKK 5.5 million received, NeuroSearch will, as per the original agreement, pay DKK 0.4 million in total to Boehringer Ingelheim and GlaxoSmithKline. The remaining DKK 5.1 million will add DKK 2.2 million to the Company's operating income, and the DKK 2.9 million will be recognised in discontinued operations.

After receipt of the DKK 5.5 million, the Company’s cash and cash equivalents totalled DKK 71 million. The payment obligation to Boehringer Ingelheim and to GlaxoSmithKline is expected to be fulfilled in H2 2017.

Allan Andersen

CEO

Contact person

Allan Andersen, CEO, mobile+45 4016 3864

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Apr
NEUR
Jeg tror ikke, at der kommer et købstilbud før til allersidst. Hvis det kommer. Jo tættere på deadli..
2
19 Apr
NEUR
Helt enig. Det er ganske enkelt en ufatteligt alt for ringe indsats af direktion og bestyrelse, hvis..
1
19 Apr
NEUR
njet du har et delvist svar fra PM fra AA lige inden kl. 16. Ikke noget konkret om salget, som de vi..
1
17 Apr
NEUR
Jeg har sendt en lille påmindelse til direktøren.   Forventer ikke svar, men så har jeg i det mindst..
1
17 Apr
NEUR
jeg tror sgu, jeg spiller lidt med - tabet må jo siges at blive begrænset ud fra kurs 3,04, hvis bes..
1
17 Apr
NEUR
Jeg tror det er siden 2010 eller 2011 de har forsøgt på at sælge det skattemæssige underskud, så hvo..
1
17 Apr
NEUR
Downside. Hvis det antages, at koste 4 millioner, at lukke ned.   Indre værdi 2,99/74×70 = kurs 2,82..
1
17 Apr
NEUR
For lige, at skære der ud i pap, 25 millioner svarer til 1 kurspoint. Ved et salg hvor de 400 millio..
1
15 Apr
NEUR
Atp sidder på 10 procent.
1

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Pomerantz Law Firm Announces the Filing of a Class Action against Myriad Genetics, Inc. and Certain Officers – MYGN
2
Jostens Unveils North Dakota State University Championship Rings and Fan Jewelry Collection
3
Rovio Entertainment Corp.: ''THE ANGRY BIRDS MOVIE 2" FLIES IN WITH ALL-STAR CAST OF NEW AND RETURNING COMEDY TALENT
4
BluDog Enters into Exclusive CBD Partnership with Natures Renewable
5
SYNACOR SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Synacor, Inc. - SYNC

Related stock quotes

NeuroSearch A/S 3.080 0.7% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2018 17:54:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180417.1 - EUROWEB6 - 2018-04-21 18:54:26 - 2018-04-21 17:54:26 - 1000 - Website: OKAY